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Background: Helicobacter pylori colonizes the gastric mucosa of more than half
of the world’s population. There is increasing evidence H. pylori protects against the
development of obesity and childhood asthma/allergies in which the development of
these diseases coincide with transient dysbiosis. However, themechanism underlying the
association of H. pylori eradication with human metabolic and immunological disorders is
not well-established. In this study, we aimed to investigate the local and systemic effects
of H. pylori eradication through untargeted fecal lipidomics and plasma metabolomics
approaches by liquid chromatography mass spectrometry (LC-MS).
Results: Our study revealed that eradication of H. pylori eradication (i.e., loss of H. pylori
and/or H. pylori eradication therapy) changed many global metabolite/lipid features,
with the majority being down-regulated. Our findings primarily show that H. pylori
eradication affects the host energy and lipid metabolism which may eventually lead to
the development of metabolic disorders.
Conclusion: These predictive metabolic signatures of metabolic and immunological
disorders following H. pylori eradication can provide insights into dynamic local and
systemic metabolism related to H. pylori eradication in modulating human health.
Keywords: fecal, plasma, Helicobacter pylori, lipidomics, metabolomics
INTRODUCTION
Helicobacter pylori is a spiral-shaped, microaerophilic, Gram-negative bacterium that colonizes the
gastric mucosa of more than half of the world’s population in which its prevalence is as high as 80%
in some developing countries (Clyne et al., 2007). Most H. pylori carriers remain asymptomatic in
their lifetimes, however, a minority group develops peptic ulcers (10–20%), gastric cancer (1–2%),
and rarely mucosa-associated lymphoid tissue (MALT) lymphoma (Kusters et al., 2006) later in life.
H. pylori is believed to have colonized the human stomach even prior to the initial migration of our
ancestors out of East Africa at least 100,000 years ago (Moodley et al., 2012). It has been postulated
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that H. pylori may be part of the human indigenous
microbiota. However, H. pylori is gradually disappearing
from the human indigenous microbiota due to development
of socioeconomic, modern hygienic practices and advent
of antibiotics. There is an growing epidemiological and
experimental evidences on the protective effects of H. pylori
against the development of obesity (Nwokolo et al., 2003;
Osawa, 2008; Francois et al., 2011; Yap et al., 2015, 2016),
childhood asthma (Chen and Blaser, 2008), allergies (Amberbir
et al., 2011), inflammatory bowel diseases (Amnon and
Robert, 2012), in which the development of these diseases
coincide with transient dysbiosis. However, the underlying
protective mechanism of H. pylori against the development
of these metabolic and immunological disorders is still not
well-established.
Over the last two decades, systems biology has emerged
as an important tool to provide insights into the role of
mammalian gut microbial metabolic interactions in influencing
an individual’s susceptibility to health and disease outcomes
(Martin et al., 2012). The emergence of systems biology coincides
with the completion of the Human Genome Project (HGP)
(Lander et al., 2001; Venter et al., 2001) and the concomitant
emergence of “omics technologies,” namely transcriptomics
(Schena et al., 1995; Lashkari et al., 1997), proteomics (Patterson
and Aebersold, 2003), metabolomics (Oliver et al., 1998;
Fiehn, 2001) and most recently, lipidomics (Han and Gross,
2003; Wenk, 2005). Lipidomics is the global characterization
of the structure and function of lipids within a living
system (Harkewicz and Dennis, 2011). Omics technologies
could be utilized to decipher the vastly complex metabolic
exchange between various biological compartments of the
H. pylori infected human host (including tissues, organs and
systemic biofluids) and his gut microbiota and ultimately
to help further understand the profound influence exerted
by H. pylori and gut bacterial microbiota on the metabolic
equilibrium of the host and, as a consequence, on his health
status.
The present study was carried out in the Malaysian
population to determine the implications ofH. pylori eradication,
particularly in the Asian community. We hypothesized that
eradication of H. pylori (loss of H. pylori and/or H. pylori
eradication therapy) may have undesirable implications on
metabolic and immunological disorders. Our earlier studies
indicate that H. pylori eradication could result in perturbation
of gut microbiome (Yap et al., 2016) and homeostasis of
human metabolic hormones involved in appetite-control and
energy metabolism (Yap et al., 2015). This may eventually
lead to the development of metabolic disorders. In this
study, we aimed to investigate the association of H. pylori
eradication with human metabolic and immunological disorders
through untargeted fecal lipidomics and plasma metabolomics
approaches by liquid chromatography mass spectrometry (LC-
MS). Fecal lipidomics enabled us to evaluate the local effects
following H. pylori eradication on the gut microbiota, whereas
plasma metabolomics reflected the systemic effects of H. pylori
eradication.
MATERIALS AND METHODS
Study Population
This study is part of the presently on-going ESSAY (Eradication
Study in Stable Adults/Youths) study in New York, the European
Center, and Malaysia. The recruitment of volunteers in Malaysia
was conducted at the University of Malaya Medical Centre
(UMMC) between June 2012 and May 2014 as described in
details in our early study (Yap et al., 2015). Firstly, healthy young
adults between the ages of 18 and 30 years old were assessed
for eligibility. The exclusion criteria for the study were diabetes,
hyper or hypothyroidism, prior gastric or bariatric surgery, prior
documented treatment ofH. pylori, antibiotic use within 4 weeks
of enrollment, steroid or other immunomodulating drugs use
within 4 weeks of enrolment, recent vaccination and Charlson
weighed comorbidity index<2. The study protocol was reviewed
and approved by Medical Ethics Committee at UMMC (Ref No.
877.1). Prior to study participation, written informed consent
was obtained from qualified volunteers. H. pylori’s status of the
qualified candidates was determined as described earlier (Yap
et al., 2015).
Sample Collection
Sample collection was performed as reported in a previous
investigation using the same study population (Yap et al., 2015).
Figure 1 illustrates the workflow for enrolment of H. pylori-
positive volunteers into the ESSAY Study. As reported previously,
57 (9.9%) of the 573 volunteers screened in the ESSAY study were
tested positive for H. pylori using both non-radioactive 13C Urea
Breath Test (UBT) and detection of anti-H. pylori antibodies and
were considered as H. pylori-positive. However, only 32 agreed
and consented to participate in the study (Yap et al., 2015).
Baseline Visit
H. pylori-positive volunteers were instructed to arrive at the
Endoscopic Unit of UMMC at 8 a.m. after 12 h of fasting. 5
ml of fasting blood was collected in EDTA-coated tube. The
protease inhibitor, 4-(2-Aminoethyl) benzenesulfonyl fluoride
hydrochloride (AEBSF) (Sigma-Aldrich, St. Louis MO), at a
concentration of 1 mg/ml, was added to the blood collection
tubes. Tubes were kept on ice until centrifuged, and plasma was
kept at −80◦C for metabolomics analysis. Fecal samples were
also collected and frozen immediately at −80◦C for lipidomics
analysis.
H. pylori Eradication Therapy
Volunteers who tested positive forH. pylori were prescribed with
a 7-day twice daily regimen and a proton pump inhibitor as per
current standard of care (amoxicillin 1,000 mg, clarithromycin
500 mg, and pantoprazole 40 mg). ≥6 weeks after completion
of the treatment protocol, H. pylori eradication was ascertained
using the non-radioactive 13C Urea Breath Test. Volunteers who
failed the first-line eradication regimen were offered second-line
eradication therapy with a 2-week twice daily regime (amoxicillin
1,000 mg, levofloxacin 500mg and rabeprazole 20 mg) (Yap et al.,
2015).
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FIGURE 1 | Summary of ESSAY Study (Yap et al., 2015).
Follow-Up Assessment
Eventually, 29 volunteers whom H. pylori infection were
successfully eradicated were recruited to the ESSAY Study. These
volunteers returned for follow-up assessment at 6, 12, and 18
months, paralleling that described for the baseline visit. The
number of volunteers returned for follow-up assessment was 29,
18, and 12 respectively (Figure 1).
Fecal Sample Preparation and Lipids
Extraction
All the organic solvents used for fecal lipids and plasma
metabolites extraction were of HPLC-grade. Methanol,
acetonitrile and isopropanol were purchased from
Friendemann Schmidt (Australia), methyl tert-butyl
ether/hexafluoroisopropanol (MTBE) was purchased from
Sigma-Aldrich (St. Louis, MO), LCMS-grade water from a
Milli-Q water purification system (EMD Millipore, Billerica,
MA) and formic acid from Sigma-Aldrich (St. Louis, MO).
Firstly, fecal slurry for each fecal sample was prepared by
combining 150mg solid fecal material in three ml of water.
The fecal slurry was then diluted with water in 1:3 ratio. The
diluted fecal slurries were then pooled into different groups
according to gender, body mass index (BMI), and race (Table S1)
to ascertain whether these variables are the confounding factors
of this study. 50µl of each diluted fecal slurry samples from
different group was placed into 2 ml centrifuge tube. Five
hundred microliters of methanol was added to each tube and
vortexed for 30 s to ensure all components were thoroughly
mixed. The mixed samples were then vortexed intermittently
for 15 min and centrifuged at 12,000 × g for 10 min to pellet
insoluble fecal material. The supernatant was then transferred to
15ml polypropylene centrifuge tubes. MTBE, 2ml per sample,
was added to each tube, vortexed to mix, and incubated at
room temperature for 10min to precipitate proteins. The lipid-
containing supernatants were transferred to new 15ml tubes, and
1.5ml of water was added to induce phase separation. Samples
were vortexed 30 s to mix, then centrifuged at 5,000 × g for
5min. After phase separation, the lipid-containing MTBE phase
forms the top layer, whilst the methanol and water forms the
bottom layer. The top layer lipid extracts were aspirated and
transferred to new tubes (Gregory et al., 2013). The lipid extracts
were dried in a CentriVap Concentrator Systems (LABCONCO,
Kansas City, MO) at 4◦C and then resuspended to a 500µl
of acetonitrile:isopropanol:water (65:30:5), vortexed for 30 s and
then centrifuged again at 12,000 × g for 5min before injecting
into liquid chromatography system.
Plasma Sample Preparation and
Metabolites Extraction
Prior to the experimental sample extraction, the ratio of
methanol to sample (v/v) for plasma metabolite extraction as
well as the resuspension volume of 95:5 water:acetonitrile were
optimized. Similar to fecal lipids extraction, the experimental
plasma samples were pooled into different groups according to
gender, body mass index (BMI), and race (Table S1) to ascertain
whether these variables are the confounding factors of this study.
Protein precipitation was conducted by adding 500µl aliquots
of ice cold methanol to 100µl aliquots of plasma samples. The
samples were instantaneously vortexed for 30 s and incubated on
ice for 20 min. After centrifugation at 12,000 × g for 10min,
the metabolite containing supernatant was removed from the
precipitated protein pellet and transferred to fresh tubes. The
supernatant samples were dried in a CentriVap Concentrator
Systems (LABCONCO, Kansas City, MO) at 4◦C and then
resuspended to a 100µl of water: acetonitrile (95:5), vortexed
for 30 s and then centrifuged again at 12,000 × g for 5min
before injecting into liquid chromatography system (Denery
et al., 2010).
Fecal Lipidomics and Plasma
Metabolomics Analysis
High-Performance Liquid Chromatography Mass
Spectrometry (LC-MS)
LC-MS analyses on the fecal lipids were performed on
a 1260 Infinity High Performance Liquid Chromatography
system coupled with a 6540 UHD Accurate-Mass Q-TOF mass
spectrometer from Agilent Technologies (Santa Clara, CA) with
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a Dual Agilent Jet Stream Electrospray Ionization (Dual AJS ESI)
source.
Analysis was performed utilizing both positive ionization and
negative ionization mode of the Dual AJS ESI source and using
All Ions MS/MS technique. All Ions MS/MS alternates between
high and low energy scans during acquisition: high energy scans
create fragment ions, low energy scans preserve the precursor
ions. Optimization of several LC parameters such as injection
volume, flowrate, and LC gradient were conducted. To ensure
the reproducibility and robustness of the data acquired, a pooled
biological quality control samples (PBQC) (constituted of pooled
aliquots of all experimental fecal samples) and a lipid standards
mixture (Avanti Polar Lipids, Alabaster, AL) (Table S2) were
periodically injected throughout the duration of analysis. The
sample run order was also assigned randomly to avoid any
systematic bias.
The aqueous mobile phase (mobile phase A) was 60%
acetonitrile and 40% water with 10mM ammonium acetate
(ThermoFisher Scientific, Waltham, MA) and the organic
mobile phase (mobile phase B) was 10% acetonitrile and 90%
isopropanol with 10mM ammonium acetate. A 10µl of extracted
fecal lipids was loaded onto Zorbax Eclipse Plus C18, 2.1 × 100
mm, 1.8µm reverse phase column (Agilent Technologies, Santa
Clara, CA) with 70% mobile phase B at 0.20 ml/min. Lipids were
eluted from the column with a gradient of 70–100%mobile phase
B over 8 min at 0.20 ml/min followed by a 7 min rinse of 100%
mobile phase B. The column was immediately re-equilibrated
under the initial conditions (isocratic hold at 70% mobile phase
B) for 10 min.
Consistent mass accuracy (<2 ppm) was maintained through
a constant infusion (2µl/min) of reference calibrants, methyl
stearate and HP-122l (with reference mass of 299.294457 and
1221.990637m/z, respectively), via a reference nebulizer. Data
were collected in both positive and negative ESI mode acquiring
in centroid mode from 100 to 1,700m/z with an acquisition rate
of 1 spectrum per second in 2 GHz extended dynamic range. The
Dual AJS ESI capillary voltage was set at 3.5 kV and nozzle voltage
was set at 1 kV; The gas temperature, drying gas flow, nebulizer
pressure, sheath gas temperature and sheath gas flow were set
at 300◦C, 8 l/min, 35 psig, 350◦C and 11 l/min, respectively.
The fragmentor and skimmer voltage were set at 175 and 65
V, correspondingly. For All Ions MS/MS, collision energy was
ramped from 0 to 40 V during each 4 s data collection cycle. All
the acquired mass spectral data was collected in a .d format.
The platform and methodology for LC-MS analyses on
the plasma metabolomics were the same as fecal lipids
mentioned above except that instead of using All Ions MS/MS
technique, only MS was used. A PBQC (constituted of
pooled of all experimental plasma samples) and an external
commercial Waters MetID Small Molecule Standard Mix
(constituted of 5-hydroxy omeprazole and omeprazole sulfone)
(Waters Corporation, Milford, MA) were periodically injected
throughout the duration of analysis.
For positive ionization, the aqueous mobile phase (mobile
phase A) was water with 0.1% formic acid and the organic
mobile phase (mobile phase B) was acetonitrile with 0.1%
formic acid. For negative ionization, the aqueous mobile phase
(mobile phase A) was water with 1 mM ammonium fluoride
(Sigma-Aldrich, St. Louis, MO) and the organic mobile phase
(mobile phase B) was acetonitrile only. The instrument control
and data acquisition were conducted using the MassHunter
Workstation Data Acquisition software, version B.05.01 (Agilent
Technologies, Santa Clara, CA). A fiveµl of extracted plasma
metabolites was loaded onto Zorbax Eclipse Plus C18, 2.1 × 100
mm, 1.8µm reverse phase column (Agilent Technologies, Santa
Clara, CA) with 5% mobile phase B at 0.45 ml/min. Metabolites
were eluted from the column with a gradient of 5–100% mobile
phase B over 22 min at 0.45 ml/min followed by a 5 min
rinse of 100% mobile phase B. The column was immediately re-
equilibrated under the initial conditions (isocratic hold at 5%
mobile phase B) for 5 min.
Data were collected in both positive and negative ESI mode
acquiring in profile mode from 70 to 1,700m/z with an
acquisition rate of 2 spectra per second in 2 GHz extended
dynamic range. The Dual AJS ESI capillary voltage was set at
3 kV; The gas temperature, drying gas flow, nebulizer pressure,
sheath gas temperature and sheath gas flow were set at 300◦C,
10 l/min, 45 psig, 250◦C, and 8 l/min, respectively. For the MS
Q-TOF, the fragmentor and skimmer voltage were set at 140 and
60 V, correspondingly. All the acquired mass spectral data was
collected in a .d format.
Data Processing and Statistical Analysis
Molecular features were extracted (Find by Molecular Feature)
with Agilent MassHunter Workstation Qualitative Analysis
software, version B.06.00 (Agilent Technologies, Santa Clara,
CA). A feature condenses the abundances from all the specified
adducts and isotopes of a compound into a single compound.
The extracted data was exported as compound exchange
file (.cef files) and imported into Mass Profiler Professional
(MPP) software, version 12.1 (Agilent Technologies, Santa
Clara, CA) for the first round of data filtering, alignment
and normalization. The generated list of compounds was
then exported as a recursive list. Subsequently, a targeted
feature finding (Find by Formula-Options) was performed
with MassHunter Workstation Qualitative Analysis software
by using the recursive list as source of formula to confirm
the identified compounds; a mass tolerance of 5 ppm was set.
The recursed data was then exported as compound exchange
file (.cef files). The recursed .cef files were then imported into
MPP to perform data processing, compounds identification
and annotation, and differential and statistical analysis between
baseline and post-H. pylori eradication groups. MPP integrated
with ID Browser was used for identification and annotation
of compounds using LC/MS Personal Compound Databases
(METLIN database). A one-way ANOVA and Tukey’s honest
significant difference (HSD) post-hoc analysis were performed to
compare the lipids/metabolites between Baseline vs. 6 months,
Baseline vs. 12 months post-H. pylori eradication and Baseline vs.
18 months post-H. pylori eradication; a two-tailed p < 0.01 and
false discovery rate (FDR) of <1% were considered significant.
A multivariate statistical analysis, i.e., Principle Component
Analysis (PCA) and Hierarchical Cluster Analysis (HCA), were
performed to observe clustering, trends and outliers in our data
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sets and to examine whether the Baseline and post-H. pylori
eradication groups could be differentiated using lipid/metabolite
profiles. For HCA analysis, clustering algorithm base on
Euclidean distance was used. Identifying small molecules/lipids
that showed significant changes between Baseline and post-
eradication groups is the most laborious and time-consuming
aspect of non-targeted metabolomics/lipidomics. Each identified
entities were manually checked through to filter out wrongly
annotated or ambiguous lipids as well as non-annotated
entities and sorted them into different categories. The
significant differentially expressed lipids/metabolites were
then mapped to pathways using Pathway Analysis integrated
in MPP.
RESULTS
Fecal Lipidomics Profiling
The LC-MS approach was used to investigate the dynamics of
fecal lipidomics profiles pre- and post-H. pylori eradication on
samples collected at Baseline prior to H. pylori eradication and
6, 12, and 18 months post-eradication. The numbers of fecal
samples that were collected in the study were 29, 23, 14, and
11 samples respectively. In order to minimize bias as well as
to identify confounding factors that may affect our findings,
the collected fecal samples were pooled into different groups
according to gender, body mass index (BMI), and race for LC-MS
analysis (Table S1).
The LC-ESI-TOF total ion chromatograms (TIC) of fecal
lipidomics for Baseline and post-eradication groups, acquired
under ESI positive and negative ionization, correspondingly,
demonstrated several peaks with different intensities, marked
by asterisks in the TIC, that were readily observed between the
Baseline and post-H. pylori eradication groups (Figures S1, S2).
Data analysis using one-way ANOVA and Tukey’s honest
significant difference (HSD) post-hoc analysis of the fecal
lipidome revealed a large number of significantly changed
molecular features between Baseline and post-H. pylori
eradication groups and a total of approximately 1,300–1,600
molecular features were extracted from a typical positive
and negative LC-ESI-TOF chromatogram between Baseline
and post-H. pylori eradication groups (Table S3). Of the
total molecular features, 513 and 434 of these features were
significantly changed between Baseline and post-eradication
groups, acquired under positive and negative ionization
respectively.
Subsequently, a multivariate statistical principal component
analysis (PCA) and hierarchical cluster analysis (HCA) were
employed to examine whether samples belonging to Baseline
and post-eradication groups could be differentiated based on
their lipids profiles. Both the two-dimensional PCA scores plots
and HCA dendrograms showed clear separation of samples
of Baseline and post-H. pylori eradication groups, under both
positive and negative ionization modes (Figures 2, 3). However,
these plots did not show distinct separation between the
different pooled fecal groups which indicated that gender,
BMI and race were not the confounding factors in this
study.
Identification of Potential Fecal Lipids
In order to identify the potential fecal lipids associated with
H. pylori eradication, the significantly altered molecular features
were identified and annotated as entities using Mass Profiler
Professional (MPP) integrated with ID Browser and LC/MS
Personal Compound Databases (METLIN database). In brief,
161, 271, and 269 entities were significantly changed when we
compared Baseline vs. 6 months, Baseline vs. 12 months, and
Baseline vs. 18 months post-H. pylori eradication, respectively
(File S1). After excluding the redundancies (e.g., lipids detected
in both ionization modes), it was found that when Baseline was
compared with 6 months-post eradication, 34 and 13 lipids were
up-regulated and down-regulated respectively. Conversely, more
lipids were down-regulated when Baseline was compared to the
12 and 18 months-post eradication groups. When Baseline was
compared with 12months-post eradication, 29 and 43 lipids were
up-regulated and down-regulated respectively. When Baseline
was compared with 18 months-post eradication, 25 and 45
lipids were up-regulated and down-regulated correspondingly
(Table S4). These lipids could be categorized into key lipid
classes such as fatty acyls, glycerolipids, glycerophospholipids,
sphingolipids, sterol lipids, prenol lipids and saccharolipids, of
which five were mapped to different biochemical pathways which
include retrograde endocannabinoid signaling and sphingolipid
metabolism (Table 1).
Plasma Metabolomics Profiling
LC-MS was also used for untargeted plasma metabolomics to
investigate the systemic changes in small molecules that may
be associated with H. pylori eradication on the same study
population. Plasma metabolomics profiling was performed on
samples collected at Baseline, 6, 12, and 18 months-postH. pylori
eradication. The number of plasma samples collected at Baseline,
6, 12, and 18 months-post H. pylori eradication were 29, 29, 18,
and 12 samples respectively. Parallel to fecal lipidomics study,
the collected plasma samples were pooled into different groups
according to gender, body mass index (BMI), and race for LC-MS
analysis (Table S1).
Several dominant differences of peak intensities, marked
by asterisks in the TIC, could be noted from the LC-
ESI-TOF TIC of plasma metabolites of Baseline and post-
eradication groups, acquired under ESI positive and negative
ionization (Figures S3, S4). One-way ANOVA and Tukey’s
HSD post-hoc analysis showed that approximately a total
of 7,000–20,000 molecular features could be extracted from
a typical positive LC-ESI-TOF chromatogram whereas only
approximately 2,000–5,000 features could be extracted from a
typical negative LC-ESI-TOF chromatogram (Table S5). Of this
enormous amount of molecular features detected, only 5,932
and 1,867 features were markedly changed between Baseline and
post-eradication groups, acquired under positive and negative
ionization respectively.
Subsequently, a multivariate statistical principal component
analysis (PCA) and hierarchical cluster analysis (HCA) were
employed to examine whether samples belonging to Baseline
and post-eradication groups could be differentiated based on
their metabolite profiles. Both of these plots also showed
Frontiers in Microbiology | www.frontiersin.org 5 March 2017 | Volume 8 | Article 536
Yap et al. Metabolic Dynamics following H. pylori Eradication
FIGURE 2 | Two-dimensional PCA scores plot of fecal lipidomics for Baseline, 6, 12, and 18 months post-H. pylori eradication, acquired under both (A)
positive and (B) negative ionization modes.
clear separation of samples between the Baseline and post-
H. pylori eradication groups, under both positive and negative
ionization modes, as illustrated in Figures 4, 5. Parallel to
fecal lipidomics analysis, both the two-dimensional PCA
scores plots and HCA dendrograms did not show distinct
separation between the different pooled plasma groups which
indicated that gender, BMI and race were not the confounding
factors.
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FIGURE 3 | HCA dendrogram of fecal lipidomics for Baseline, 6, 12, and
18 months post-H. pylori eradication, acquired under both (A) positive
and (B) negative ionization modes.
Identification of Potential Small Molecules
in Plasma
The same identification and annotation approaches were used
for both lipid and metabolite datasets. Additionally, for plasma
metabolomics, exogenous metabolites and xenobiotics were also
filtered out as we were only interested in investigating the
effects ofH. pylori eradication on the human endogenous plasma
metabolomes. To sum up, a total of 1,080, 1,125, and 1,262
entities were significantly changed for comparison of Baseline vs.
6 months, Baseline vs. 12 months, and Baseline vs. 18 months
post-H. pylori eradication, respectively (File S2).
As mentioned above, although the same metabolite could be
identified by the ID Browser as several different entities, are
actually the components of one compound. After removing the
redundant compounds, it was found that when the Baseline
samples were compared with 6 months-post eradication, there
were 222 and 348 metabolites that were up-regulated and
down-regulated respectively. When Baseline was compared
with 12 months-post eradication, the up- and down-regulated
metabolites were 239 and 359 correspondingly. Conversely,
only 45 metabolites were up-regulated but there were 551
metabolites down-regulated when Baseline was compared with
18 months-post eradication group (Table S6). These significantly
changed metabolites included amino acids, purines, pyrimidines,
cofactors, polar lipids etc. Among these significantly expressed
metabolites, 71 of them could be categorized into 22major classes
of metabolites and mapped to different biochemical pathways
(Table 2). From the Pathway Analysis, porphyrin and chlorophyll
metabolism was found to be the major perturbed pathway
followed by tryptophan metabolism and bile acid biosynthesis.
When plasma metabolome from Baseline was compared
with post-H. pylori eradication groups, a number of fatty acids
and sphingolipids involved in biosynthesis of unsaturated
fatty acids and sphingolipid metabolism respectively were
down- regulated post-H. pylori eradication. Two metabolites,
melatonin and 5-Hydroxytryptophan, which are involved
in the melatonin biosynthesis were also found to be down-
regulated in post-H. pylori eradication groups. Also, propinol
adenylate (propanoate metabolism), adenosylcobalamin
(riboflavin metabolism) as well as UDP L-rhamnose, and
2,4-Bis(acetamido)-2,4,6-trideoxy-beta-L-altropyranose (amino
sugar and nucleotide sugar metabolism) were also down-
regulated in post-H. pylori eradication groups. Conversely,
pseudouridine, oxytocin, angiotensin I, and prequalene
diphosphate, involved in pyrimidine metabolism, cAMP
signaling pathway, renin-angiotensin system, and cholesterol
biosynthesis respectively, were found to be up-regulated
following H. pylori eradication. Taurocholic acid and
taurochenodeoxycholic acid which are involved in primary
bile acid biosynthesis were up-regulated at 6 and 12 months-post
eradication but they were down-regulated at 18 months-post
eradication. Interestingly, there were five metabolites that
belong to the class of tetrapyrroles and derivatives which are
involved in bilirubin degradation down-regulated at the 12 and
18 months-post H. pylori eradication. Besides, four porphyrins
which also belong to the class of tetrapyrroles and derivatives
that involved in heme biosynthesis were also found to be
down-regulated at 18 months post-eradication. Metabolites
involved in tricarboxylic acid cycle (TCA), citric acid and flavin
adenine dinucleotide (FAD), were found to be up-regulated
6 months post-eradication but they were down-regulated at
Frontiers in Microbiology | www.frontiersin.org 7 March 2017 | Volume 8 | Article 536
Yap et al. Metabolic Dynamics following H. pylori Eradication
TABLE 1 | Selected significantly expressed fecal lipids (p < 0.001) between Baseline and post-H. pylori eradication groups.
KEGG/HMDB/
LMID
Lipid Class Pathway m/z RT (min) Comparison of
expression
level at 6
months post-
eradication to
Baselinea
Comparison of
expression
level at 12
months post-
eradication to
Baselinea
Comparison of
expression
level at 18
months post-
eradication to
Baselinea
C19913/
LMFA08020002
Anandamide 0-phosphate Fatty acyls Retrograde
endocannabinoid
signaling
445.2819 14.79 +11.72 +3.40 −3.31
C00836/ Sphinganine Sphingolipids Sphingolipid
metabolism
302.3567 1.56 +1.77 +1.30 +0.82
HMDB00269/
LMSP01020001
C12144/ Phytosphingosine Sphingolipids Sphingolipid
metabolism
318.2937 1.45 −19.48 −18.77 −4.25
HMDB04610/
LMSP01030001
HMDB13244/
LMSL01040002
Lipid A -disaccharide-1-P Saccharolipids − 661.4385 10.03 +0.38 +3.98 +16.15
LMPR04000022 32,35-
anhydrobacteriohopaneterol
Prenol lipids − 527.4471 11.54 +0.25 +0.21 −13.32
aExpression level indicates log2 fold change (FC). + indicates up-regulated in post-eradication group; − indicates down-regulated in post-eradication group.
12 and 18 months post-eradication. N1,N12-Diacetylspermine
and 3-Acetamidopropanal are intermediates that involved
in polyamine metabolism. Both of these metabolites were
up-regulated at 6 and 12 months post-H. pylori eradication.
At 18 months post-eradication, N1,N12-Diacetylspermine
remained unchanged but 3-Acetamidopropanal was found to be
down-regulated (Table 2).
DISCUSSIONS
Biological Significance of the Fecal
Lipidomics Analysis
Fecal lipidomics analysis allows us to assess the human GI
functions broadly and non-invasively and hence, it should reflect
the GI health and functions (Gregory et al., 2013). Lipids are
essential to intestinal biology as it is more stable than various
metabolites, and more conserved across microbiota (Gregory
et al., 2013). A series of lipids, which could elucidate the local
effects of H. pylori eradication on the gut microbiota and
modulation of energy were identified.
The endocannabinoid system is a vital endogenous signaling
system that comprises of the cannabinoid receptors, their
endogenous ligands (the endocannabinoids), and the enzymes
catalyzing anabolism and catabolism of endocannabinoid
(Di Marzo et al., 2004). This system is recognized to be
involved in a extensive range of physiological functions and
pathophysiological conditions (Engeli et al., 2005; Pacher et al.,
2006; DiMarzo, 2008; Engeli, 2008; Pataky et al., 2013). Obesity is
characterized by altered gut microbiota, low grade inflammation
and dysregulation of endocannabinoid system, in majority of the
cases overactive of the system (Muccioli et al., 2010; Geurts et al.,
2011). In this study, Anandamide 0-phosphate was found to be
up-regulated at 6 and 12 months following H. pylori eradication
but it was then down-regulated at 18 months post-eradication.
Anandamide 0-phosphate is one of the intermediates in the
biosynthesis of anandamine (KEGG: map04723). Anandamide
(also known as N-arachidonoylethanolamine or AEA) is an
endocannabinoid that is synthesized from N-arachidonoyl
phosphatidylethanolamine (NAPE) by numerous pathways or
alternatively, it can also be synthesized from free arachidonic
acid and ethanolamine by the reversal action of a fatty acid
amide hydrolase (FAAH) (Sugiura, 2008; Wang and Ueda, 2009).
The marked changes in expression of Anandamide 0-phosphate
could be linked with the perturbation of gut microbiota post-
H. pylori eradication which in turn causes dysregulation of the
endocannabinoid system and subsequently affect the regulation
of energy metabolism and therefore, lead to the development of
obesity.
Phytosphingosine, sphinganine and ceramide that are
involved in sphingolipid metabolism (KEGG: map00600) were
found to be changed significantly in this study. Ceramide is
a main molecule in sphingolipid metabolism and a precursor
of complex sphingolipids (Sugiura et al., 2002; Hannun and
Obeid, 2008). Sphingolipids are important signal molecules
that mediate several biological functions for instance cell
proliferation, inflammation, and apoptosis (Futerman and
Hannun, 2004; Hannun and Obeid, 2008; Morad and Cabot,
2013). Phytosphingosine detected in fecal samples was down-
regulated post-H. pylori eradication and we believe that it could
be related to the reduced inflammation of the stomach lining
after H. pylori eradication. On the contrary, sphinganine (also
known as dihydrosphingosine) detected in the fecal samples
was found to be up-regulated significantly 6 and 12 months
post-eradication. The biological significance of this conflicting
observation was unknown.
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FIGURE 4 | Two-dimensional PCA of plasma metabolomics for Baseline, 6 months, 12 months, and 18 months post-H. pylori eradication, acquired
under both (A) positive and (B) negative ionization modes.
One of the most interesting findings of this study is
Lipid A-disaccharide-1-P was significantly elevated 12 and 18
months post-H. pylori eradication. Lipid A, one of the three
structural components of the lipopolysaccharide (LPS) causes
the pathophysiological effects associated with Gram-negative
bacteria infections (Lodowska et al., 2007). Gram-negative
bacteria such as Bacteroidetes and Proteobacteria (including
H. pylori) are dominant microorganisms in the gut (Ley et al.,
2005; Yap et al., 2016). The up-regulation of Lipid A 12 and 18
months post-H. pylori eradication could probably be associated
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FIGURE 5 | HCA dendrogram of plasma metabolomics for Baseline, 6,
12, and 18 post-H. pylori eradication, acquired under both (A) positive
and (B) negative ionization modes.
with the perturbation of microbiota in the gut followingH. pylori
eradication. In our previous fecal metagenomics study, we
found a transient loss of H. pylori instantaneously following
H. pylori eradication but reappeared at 12–18 months (Yap
et al., 2016). Due to the overlapping time points, it is likely that
H. pylori employs the advantage of ecological niche to replicate
intracellularly and survive the anti-bacterial treatment (Yap et al.,
2016). Nevertheless, we could not prove that the Lipid Awas from
H. pylori.
A Proteobacteria hopanoid named 32,35-
anhydrobacteriohopaneterol (Talbot et al., 2007) was found
to be down-regulated at 18 months post-eradication. Hopanoids
are bacterial pentacyclic triterpenoids that are analogous to
eukaryotic steroids structurally and biosynthetically (Ourisson
et al., 1987; Doughty et al., 2011; Welander et al., 2012), but
their cellular roles are poorly understood (Doughty et al., 2014).
Hopanoids may play a role in the alteration of cell membrane
permeability in adaptation to extreme environmental conditions
in many bacteria. They are formed in the aerial hyphae of
the prokaryotic soil bacteria Streptomyces which is believed
to minimize water evaporation across the membrane (Poralla
et al., 2000). In the actinomycete Frankia, the hopanoids in
diazovesicle membranes probably restrict the entry of oxygen
by building the lipid bilayer tighter and more compact (Berry
et al., 1993). The Proteobacteria in the gut including H. pylori
may be expressing 32,35-anhydrobacteriohopaneterol to adapt
the hostile environment in the gut. The perturbation of gut
microbiota following H. pylori eradication therapy may be the
reason of the reduced expression of this hopanoid.
Biological Significance of the Plasma
Metabolomics Analysis
Plasma metabolites is an integrative biofluid that incorporates
the functions and phenotypes of many different parts of
body in one sample and hence provide an overview of
“metabolic footprint” of many areas of metabolism in the
human body (Dunn et al., 2011). The identified potential
small molecules detected cover the essential metabolic pathways,
hence allowing the determination of key intermediates of heme
biosynthesis and bilirubin degradation, amino acid metabolisms,
lipid metabolism, and energy metabolism (tricarboxylic acid
cycle). Numerous metabolites in the plasma were significantly
changed following H. pylori eradication, with the majority
being down-regulated in the post-H. pylori eradication groups.
A sophisticated interaction of how the changes in the gut
microbiota (local) after H. pylori eradication influence the
systemic changes of a human body could be observed.
Altered Energy Metabolism and Its
Association with Metabolic Disorders
Melatonin and 5-Hydroxytryptophan involved in melatonin
biosynthesis were down-regulated following H. pylori
eradication. Recent experimental evidence suggested that
melatonin may influence food intake, energy expenditure, the
accumulation of energy in adipose tissue, insulin secretion and
glycemic control (Peschke et al., 2006; Picinato et al., 2008;
Prokopenko et al., 2009; Amaral et al., 2014b). It has been
proposed that the reduction in melatonin production may
induce insulin resistance, glucose intolerance, sleep disturbance,
and metabolic circadian disorganization characterizing a state of
chrono-disruption leading to metabolic disorders such as obesity
Frontiers in Microbiology | www.frontiersin.org 10 March 2017 | Volume 8 | Article 536
Yap et al. Metabolic Dynamics following H. pylori Eradication
T
A
B
L
E
2
|
S
e
le
c
te
d
s
ig
n
ifi
c
a
n
tl
y
e
x
p
re
s
s
e
d
p
la
s
m
a
m
e
ta
b
o
li
te
s
(p
<
0
.0
0
1
)
b
e
tw
e
e
n
B
a
s
e
li
n
e
a
n
d
p
o
s
t-
H
.
p
y
lo
ri
e
ra
d
ic
a
ti
o
n
g
ro
u
p
s
.
K
E
G
G
/
H
M
D
B
/
L
M
ID
M
e
ta
b
o
li
te
C
la
s
s
P
a
th
w
a
y
m
/z
R
T
(m
in
)
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
6
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
1
2
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
1
8
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
0
0
3
4
5
/
H
M
D
B
0
1
3
1
6
6
-P
h
o
sp
h
o
g
lu
c
o
n
ic
a
c
id
C
a
rb
o
h
yd
ra
te
s
a
n
d
c
a
rb
o
h
yd
ra
te
c
o
n
ju
g
a
te
s
P
e
n
to
se
P
h
o
sp
h
a
te
P
a
th
w
a
y
1
3
9
.0
1
9
6
3
.1
2
+
1
3
.2
4
−
−
C
0
1
5
9
8
/
H
M
D
B
0
1
3
8
9
M
e
la
to
n
in
In
d
o
le
s
a
n
d
d
e
riv
a
tiv
e
s
Tr
yp
to
p
h
a
n
m
e
ta
b
o
lis
m
M
e
la
to
n
in
b
io
sy
n
th
e
si
s
2
3
3
.1
2
8
2
5
.0
0
−
1
0
.2
6
−
1
2
.0
6
−
1
2
.0
6
C
0
1
0
1
7
/
H
M
D
B
0
0
4
7
2
5
-H
yd
ro
xy
tr
yp
to
p
h
a
n
In
d
o
le
s
a
n
d
d
e
riv
a
tiv
e
s
Tr
yp
to
p
h
a
n
m
e
ta
b
o
lis
m
M
e
la
to
n
in
b
io
sy
n
th
e
si
s
2
2
1
.0
9
1
6
1
.7
0
−
1
.1
4
−
6
.6
0
−
9
.7
8
C
0
0
4
6
3
/
H
M
D
B
0
0
7
3
8
In
d
o
le
In
d
o
le
s
a
n
d
d
e
riv
a
tiv
e
s
Tr
yp
to
p
h
a
n
m
e
ta
b
o
lis
m
1
1
6
.0
5
0
7
2
.1
3
+
2
.1
9
+
1
.0
7
−
7
.5
2
C
0
5
6
3
5
/
H
M
D
B
0
0
7
6
3
5
-H
yd
ro
xy
in
d
o
le
a
c
e
tic
a
c
id
In
d
o
le
s
a
n
d
d
e
riv
a
tiv
e
s
Tr
yp
to
p
h
a
n
m
e
ta
b
o
lis
m
1
9
0
.0
5
0
9
1
.2
1
+
1
.1
0
−
4
.3
8
−
1
3
.9
9
C
0
0
3
2
8
/
H
M
D
B
0
0
6
8
4
K
yn
u
re
n
in
e
B
e
n
ze
n
e
a
n
d
su
b
st
itu
te
d
d
e
riv
a
tiv
e
s
Tr
yp
to
p
h
a
n
m
e
ta
b
o
lis
m
2
0
9
.0
9
1
8
1
.4
3
−
5
.7
8
+
2
.6
0
−
1
5
.7
1
C
0
5
6
4
7
/
H
M
D
B
1
2
9
4
8
F
o
rm
yl
-5
-
h
yd
ro
xy
ky
n
u
re
n
a
m
in
e
B
e
n
ze
n
e
a
n
d
su
b
st
itu
te
d
d
e
riv
a
tiv
e
s
Tr
yp
to
p
h
a
n
m
e
ta
b
o
lis
m
2
0
7
.0
7
7
0
1
.2
2
+
2
.7
2
+
0
.9
1
2
−
1
5
.7
4
C
0
1
8
2
9
/
H
M
D
B
0
0
2
4
8
T
h
yr
o
xi
n
e
B
e
n
ze
n
e
a
n
d
su
b
st
itu
te
d
d
e
riv
a
tiv
e
s
Ty
ro
si
n
e
m
e
ta
b
o
lis
m
T
h
yr
o
id
h
o
rm
o
n
e
sy
n
th
e
si
s
7
7
7
.6
9
4
2
1
2
.6
4
+
2
.3
9
−
0
.4
3
−
9
.2
5
C
1
5
5
2
2
/
H
M
D
B
0
2
2
8
1
4
a
-
H
yd
ro
xy
te
tr
a
h
yd
ro
b
io
p
te
rin
P
te
rid
in
e
s
a
n
d
d
e
riv
a
tiv
e
s
Tr
yp
to
p
h
a
n
m
e
ta
b
o
lis
m
P
h
e
n
yl
a
la
n
in
e
a
n
d
ty
ro
si
n
e
m
e
ta
b
o
lis
m
3
0
2
.0
8
4
0
5
.9
3
−
1
4
.4
0
−
7
.8
0
−
1
8
.5
7
C
0
9
3
3
2
/
H
M
D
B
0
6
8
2
5
Te
tr
a
h
yd
ro
fo
ly
l-
[G
lu
](2
)
P
te
rid
in
e
s
a
n
d
d
e
riv
a
tiv
e
s
F
o
la
te
b
io
sy
n
th
e
si
s
5
9
7
.2
0
3
3
3
.2
1
+
1
6
.9
8
+
1
1
.4
4
−
8
.5
4
C
0
5
8
4
3
/
H
M
D
B
0
4
1
9
4
N
-M
e
th
yl
-4
-p
yr
id
o
n
e
-3
-
c
a
rb
o
xa
m
id
e
P
yr
id
in
e
s
a
n
d
d
e
riv
a
tiv
e
s
N
ic
o
tin
a
te
a
n
d
n
ic
o
tin
a
m
id
e
m
e
ta
b
o
lis
m
1
5
3
.0
6
5
3
0
.9
6
+
2
.9
6
−
8
.3
0
−
8
.3
0
C
0
0
7
9
1
/
H
M
D
B
0
0
5
6
2
C
re
a
tin
in
e
A
zo
lin
e
s
A
rg
in
in
e
a
n
d
p
ro
lin
e
m
e
ta
b
o
lis
m
1
1
2
.0
5
1
7
0
.6
7
+
2
.2
6
−
0
.5
7
−
1
9
.8
7
(C
o
n
ti
n
u
e
d
)
Frontiers in Microbiology | www.frontiersin.org 11 March 2017 | Volume 8 | Article 536
Yap et al. Metabolic Dynamics following H. pylori Eradication
T
A
B
L
E
2
|
C
o
n
ti
n
u
e
d
K
E
G
G
/
H
M
D
B
/
L
M
ID
M
e
ta
b
o
li
te
C
la
s
s
P
a
th
w
a
y
m
/z
R
T
(m
in
)
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
6
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
1
2
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
1
8
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
0
0
2
6
2
/
H
M
D
B
0
0
1
5
7
H
yp
o
xa
n
th
in
e
Im
id
a
zo
p
yr
im
id
in
e
s
P
u
rin
e
m
e
ta
b
o
lis
m
1
3
7
.0
4
5
2
0
.8
0
−
2
.6
9
+
1
0
.1
9
−
4
.3
2
C
0
0
1
4
7
/
H
M
D
B
0
0
0
3
4
A
d
e
n
in
e
Im
id
a
zo
p
yr
im
id
in
e
s
P
u
rin
e
m
e
ta
b
o
lis
m
1
3
4
.0
4
7
1
0
.9
3
+
3
.2
0
−
1
4
.8
8
−
1
4
.8
8
C
0
4
3
7
6
/
H
M
D
B
0
1
3
0
8
5
′ -
P
h
o
sp
h
o
rib
o
sy
l-
N
-
fo
rm
yl
g
ly
c
in
a
m
id
e
(F
G
A
R
)
G
ly
c
in
a
m
id
e
R
ib
o
n
u
c
le
o
tid
e
s
P
u
rin
e
m
e
ta
b
o
lis
m
3
3
2
.0
8
5
1
1
2
.2
9
−
1
3
.9
8
−
9
.9
4
−
1
8
.7
5
C
0
1
2
6
1
/
H
M
D
B
0
1
3
4
0
P
1
,P
4
-B
is
(5
′ -
g
u
a
n
o
sy
l)
te
tr
a
p
h
o
sp
h
a
te
(G
p
p
p
p
G
)
(5
′ -
>
5
′ )
-
d
in
u
c
le
o
tid
e
s
P
u
rin
e
m
e
ta
b
o
lis
m
8
6
9
.0
4
7
7
1
4
.6
5
−
1
3
.6
5
−
6
.6
8
−
1
1
.4
5
C
0
0
3
6
6
/
H
M
D
B
0
0
2
8
9
U
ric
a
c
id
A
lk
a
lo
id
s
a
n
d
d
e
riv
a
tiv
e
s
P
u
rin
e
m
e
ta
b
o
lis
m
1
6
7
.0
2
1
2
0
.5
9
+
3
.5
6
+
1
.9
2
−
1
7
.5
0
C
0
2
0
6
7
/
H
M
D
B
0
0
7
6
7
P
se
u
d
o
u
rid
in
e
N
u
c
le
o
si
d
e
a
n
d
n
u
c
le
o
tid
e
a
n
a
lo
g
s
P
yr
im
id
in
e
m
e
ta
b
o
lis
m
2
4
3
.0
6
2
4
0
.7
6
+
3
.0
0
+
1
.6
4
+
1
.6
4
C
0
5
9
8
3
/
H
M
D
B
0
6
8
0
6
P
ro
p
in
o
la
d
e
n
yl
a
te
P
u
rin
e
n
u
c
le
o
tid
e
s
P
ro
p
a
n
o
a
te
m
e
ta
b
o
lis
m
4
2
6
.0
8
0
1
0
.6
2
−
1
.8
5
−
1
2
.5
2
−
1
7
.2
4
C
0
2
1
9
9
/
H
M
D
B
1
2
3
0
5
U
D
P
-L
-r
h
a
m
n
o
se
P
yr
im
id
in
e
n
u
c
le
o
tid
e
s
A
m
in
o
su
g
a
r
a
n
d
n
u
c
le
o
tid
e
su
g
a
r
m
e
ta
b
o
lis
m
5
7
3
.0
5
0
5
0
.6
9
−
1
4
.9
8
−
1
4
.9
8
−
1
4
.9
8
C
1
9
9
7
2
2
,4
-B
is
(a
c
e
ta
m
id
o
)-
2
,4
,6
-
tr
id
e
o
xy
-b
e
ta
-
L
-a
ltr
o
p
yr
a
n
o
se
−
A
m
in
o
su
g
a
r
a
n
d
n
u
c
le
o
tid
e
su
g
a
r
m
e
ta
b
o
lis
m
2
4
7
.1
2
8
7
2
.3
3
−
6
.1
0
−
2
.5
5
−
1
5
.8
8
C
0
0
1
5
8
/
H
M
D
B
0
0
0
9
4
C
itr
ic
a
c
id
C
a
rb
o
xy
lic
a
c
id
s
a
n
d
d
e
riv
a
tiv
e
s
Tr
ic
a
rb
o
xy
lic
a
c
id
c
yc
le
(T
C
A
)
2
1
5
.0
1
5
4
0
.7
1
+
4
.4
1
−
3
.2
1
−
8
.3
8
C
0
2
2
3
7
/
H
M
D
B
0
0
8
0
5
R
-(
+
)-
P
yr
ro
lid
o
n
e
-5
-
c
a
rb
o
xy
lic
a
c
id
C
a
rb
o
xy
lic
a
c
id
s
a
n
d
d
e
riv
a
tiv
e
s
D
-g
lu
ta
m
in
e
a
n
d
D
-g
lu
ta
m
a
te
m
e
ta
b
o
lis
m
1
3
0
.0
4
9
6
6
.1
3
+
3
.7
4
−
1
4
.9
7
−
1
4
.9
7
C
1
1
6
8
4
M
E
T-
E
n
ke
p
h
a
lin
C
a
rb
o
xy
lic
a
c
id
s
a
n
d
d
e
riv
a
tiv
e
s
N
e
u
ro
a
c
tiv
e
lig
a
n
d
-r
e
c
e
p
to
r
in
te
ra
c
tio
n
5
9
1
.2
6
0
5
1
6
.8
4
−
6
.6
3
+
4
.6
1
−
4
.9
7
C
0
4
4
6
2
/
H
M
D
B
1
2
2
6
6
N
-S
u
c
c
in
yl
-2
-a
m
in
o
-6
-
ke
to
p
im
e
la
te
C
a
rb
o
xy
lic
a
c
id
s
a
n
d
d
e
riv
a
tiv
e
s
Ly
si
n
e
b
io
sy
n
th
e
si
s
2
8
5
.1
3
2
0
7
.8
0
+
2
.5
3
−
5
.4
2
−
1
2
.2
9
C
0
4
1
4
8
/
H
M
D
B
0
6
3
4
4
A
lp
h
a
-N
-P
h
e
n
yl
a
c
e
ty
l-
L
-
g
lu
ta
m
in
e
C
a
rb
o
xy
lic
a
c
id
s
a
n
d
d
e
riv
a
tiv
e
s
P
h
e
n
yl
a
la
n
in
e
m
e
ta
b
o
lis
m
2
6
5
.1
1
8
3
6
.1
2
+
1
.6
5
+
1
1
.4
1
−
1
2
.2
1
(C
o
n
ti
n
u
e
d
)
Frontiers in Microbiology | www.frontiersin.org 12 March 2017 | Volume 8 | Article 536
Yap et al. Metabolic Dynamics following H. pylori Eradication
T
A
B
L
E
2
|
C
o
n
ti
n
u
e
d
K
E
G
G
/
H
M
D
B
/
L
M
ID
M
e
ta
b
o
li
te
C
la
s
s
P
a
th
w
a
y
m
/z
R
T
(m
in
)
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
6
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
1
2
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
1
8
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
1
1
5
8
8
c
is
-3
-(
C
a
rb
o
xy
-e
th
yl
)-
3
,5
-
c
yc
lo
-h
e
xa
d
ie
n
e
-1
,2
-d
io
l
C
a
rb
o
xy
lic
a
c
id
s
a
n
d
d
e
riv
a
tiv
e
s
P
h
e
n
yl
a
la
n
in
e
m
e
ta
b
o
lis
m
1
8
3
.0
6
7
0
1
.1
1
+
2
2
.3
4
+
4
.1
3
−
1
.8
7
C
0
0
7
4
6
/
H
M
D
B
0
2
8
6
5
O
xy
to
c
in
C
a
rb
o
xy
lic
a
c
id
s
a
n
d
d
e
riv
a
tiv
e
s
c
A
M
P
si
g
n
a
lin
g
p
a
th
w
a
y
5
2
1
.2
5
4
4
7
.7
9
+
8
.9
4
+
1
6
.8
9
+
1
.9
9
C
0
3
4
1
3
/
H
M
D
B
0
2
1
7
2
N
1
,N
1
2
-D
ia
c
e
ty
ls
p
e
rm
in
e
C
a
rb
o
xy
lic
a
c
id
s
a
n
d
d
e
riv
a
tiv
e
s
P
o
ly
a
m
in
e
m
e
ta
b
o
lis
m
3
0
9
.2
2
5
6
9
.8
0
+
4
.6
3
+
1
6
.5
8
−
C
0
0
0
1
6
/
H
M
D
B
0
1
2
4
8
F
la
vi
n
a
d
e
n
in
e
d
in
u
c
le
o
tid
e
(F
A
D
)
F
la
vi
n
n
u
c
le
o
tid
e
s
−
7
8
6
.1
6
4
3
6
.3
6
+
2
.0
4
−
9
.5
8
−
9
.5
8
H
M
D
B
1
1
6
1
2
6
-H
yd
ro
xy
F
la
vi
n
a
d
e
n
in
e
d
in
u
c
le
o
tid
e
F
la
vi
n
n
u
c
le
o
tid
e
s
−
8
1
9
.1
8
3
0
9
.3
0
+
1
.3
4
−
1
.7
5
−
7
.4
4
C
0
0
1
9
4
/
H
M
D
B
0
2
0
8
6
A
d
e
n
o
sy
lc
o
b
a
la
m
in
−
P
o
rp
h
yr
in
a
n
d
c
h
lo
ro
p
h
yl
l
m
e
ta
b
o
lis
m
R
ib
o
fla
vi
n
m
e
ta
b
o
lis
m
6
9
3
.3
3
9
7
1
8
.9
6
−
1
8
.2
1
−
1
8
.2
1
−
1
8
.2
1
C
0
3
2
6
2
/
H
M
D
B
0
1
2
6
1
C
o
p
ro
p
o
rp
h
yr
in
o
g
e
n
III
Te
tr
a
p
yr
ro
le
s
a
n
d
d
e
riv
a
tiv
e
s
P
o
rp
h
yr
in
a
n
d
c
h
lo
ro
p
h
yl
l
m
e
ta
b
o
lis
m
H
e
m
e
b
io
sy
n
th
e
si
s
3
2
9
.1
5
0
4
1
.1
9
+
2
.5
7
+
2
.2
3
−
1
1
.8
7
C
0
2
1
9
1
/
H
M
D
B
0
0
2
4
1
P
ro
to
p
o
rp
h
yr
in
IX
Te
tr
a
p
yr
ro
le
s
a
n
d
d
e
riv
a
tiv
e
s
P
o
rp
h
yr
in
a
n
d
c
h
lo
ro
p
h
yl
l
m
e
ta
b
o
lis
m
H
e
m
e
b
io
sy
n
th
e
si
s
5
8
0
.2
9
2
0
1
7
.6
4
+
1
.3
1
+
5
.3
2
−
6
.3
H
M
D
B
0
0
6
6
8
H
e
m
a
to
p
o
rp
h
yr
in
Te
tr
a
p
yr
ro
le
s
a
n
d
d
e
riv
a
tiv
e
s
P
o
rp
h
yr
in
a
n
d
c
h
lo
ro
p
h
yl
l
m
e
ta
b
o
lis
m
H
e
m
e
b
io
sy
n
th
e
si
s
5
9
9
.2
8
5
6
1
2
.3
6
+
3
.5
8
−
5
.6
5
−
9
.7
3
H
M
D
B
0
0
6
8
3
H
a
rd
e
ro
p
o
rp
h
yr
in
Te
tr
a
p
yr
ro
le
s
a
n
d
d
e
riv
a
tiv
e
s
P
o
rp
h
yr
in
a
n
d
c
h
lo
ro
p
h
yl
l
m
e
ta
b
o
lis
m
H
e
m
e
b
io
sy
n
th
e
si
s
6
2
6
.2
9
5
8
1
9
.4
0
−
6
.8
9
+
5
.6
9
−
3
.2
5
C
0
0
5
0
0
/
H
M
D
B
0
2
3
0
9
B
ili
ve
rd
in
IX
Te
tr
a
p
yr
ro
le
s
a
n
d
d
e
riv
a
tiv
e
s
P
o
rp
h
yr
in
a
n
d
c
h
lo
ro
p
h
yl
l
m
e
ta
b
o
lis
m
5
8
3
.2
5
5
1
1
4
.1
9
+
1
.9
4
−
2
.8
5
−
1
0
.5
7
(C
o
n
ti
n
u
e
d
)
Frontiers in Microbiology | www.frontiersin.org 13 March 2017 | Volume 8 | Article 536
Yap et al. Metabolic Dynamics following H. pylori Eradication
T
A
B
L
E
2
|
C
o
n
ti
n
u
e
d
K
E
G
G
/
H
M
D
B
/
L
M
ID
M
e
ta
b
o
li
te
C
la
s
s
P
a
th
w
a
y
m
/z
R
T
(m
in
)
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
6
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
1
2
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
1
8
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
0
5
7
9
3
/
H
M
D
B
0
4
1
5
9
L
-U
ro
b
ili
n
Te
tr
a
p
yr
ro
le
s
a
n
d
d
e
riv
a
tiv
e
s
P
o
rp
h
yr
in
a
n
d
c
h
lo
ro
p
h
yl
l
m
e
ta
b
o
lis
m
:
B
ili
ru
b
in
d
e
g
ra
d
a
tio
n
5
9
5
.3
4
8
0
1
4
.9
3
+
1
0
.8
2
−
3
.1
6
−
4
.6
8
C
0
5
7
9
4
/
H
M
D
B
0
4
1
6
0
I-
U
ro
b
ili
n
Te
tr
a
p
yr
ro
le
s
a
n
d
d
e
riv
a
tiv
e
s
P
o
rp
h
yr
in
a
n
d
c
h
lo
ro
p
h
yl
l
m
e
ta
b
o
lis
m
:
B
ili
ru
b
in
d
e
g
ra
d
a
tio
n
5
9
1
.3
1
6
3
1
5
.0
8
−
0
.8
5
−
1
2
.8
3
−
1
4
.4
0
C
0
5
7
9
0
/
H
M
D
B
0
1
8
9
8
M
e
so
b
ili
ru
b
in
o
g
e
n
Te
tr
a
p
yr
ro
le
s
a
n
d
d
e
riv
a
tiv
e
s
P
o
rp
h
yr
in
a
n
d
c
h
lo
ro
p
h
yl
l
m
e
ta
b
o
lis
m
:
B
ili
ru
b
in
d
e
g
ra
d
a
tio
n
6
1
5
.3
1
4
9
1
5
.0
5
+
3
.6
4
−
9
.6
0
−
9
.6
0
C
0
5
7
8
9
/
H
M
D
B
0
4
1
5
7
L
-U
ro
b
ili
n
o
g
e
n
Te
tr
a
p
yr
ro
le
s
a
n
d
d
e
riv
a
tiv
e
s
P
o
rp
h
yr
in
a
n
d
c
h
lo
ro
p
h
yl
l
m
e
ta
b
o
lis
m
:
B
ili
ru
b
in
d
e
g
ra
d
a
tio
n
5
9
7
.3
6
3
3
1
2
.7
2
−
6
.6
0
−
4
.6
9
−
8
.1
3
C
1
8
1
7
0
/
H
M
D
B
1
2
8
8
0
3
-A
c
e
ta
m
id
o
p
ro
p
a
n
a
l
C
a
rb
o
n
yl
c
o
m
p
o
u
n
d
s
S
p
e
rm
in
e
a
n
d
sp
e
rm
id
in
e
d
e
g
ra
d
a
tio
n
P
o
ly
a
m
in
e
m
e
ta
b
o
lis
m
1
1
4
.0
5
6
2
0
.5
1
+
3
.5
7
+
3
.2
7
−
1
3
.0
6
C
0
0
8
7
3
/
H
M
D
B
6
1
1
9
6
A
n
g
io
te
n
si
n
I
P
o
ly
p
e
p
tid
e
s
R
e
n
in
-
a
n
g
io
te
n
si
n
sy
st
e
m
1
3
1
8
.6
6
1
3
2
2
.5
0
+
1
7
.6
8
+
1
4
.7
2
+
1
1
.7
6
C
1
7
9
3
5
C
ys
te
in
yl
d
o
p
a
−
Ty
ro
si
n
e
m
e
ta
b
o
lis
m
3
1
7
.0
8
1
7
0
.6
7
+
6
.5
4
+
8
.3
2
−
8
.2
8
C
1
7
2
4
0
p
-H
yd
ro
xy
b
e
n
zy
l-
d
e
su
lp
h
o
g
lu
c
o
si
n
o
la
te
−
G
lu
c
o
si
n
o
la
te
b
io
sy
n
th
e
si
s
2
-O
xo
c
a
rb
o
xy
lic
a
c
id
m
e
ta
b
o
lis
m
3
4
6
.0
9
3
9
1
.2
0
−
2
.4
1
+
1
.3
5
−
1
4
.4
2
C
0
6
4
2
8
/
H
M
D
B
0
1
9
9
9
/
L
M
FA
0
1
0
3
0
7
6
1
E
ic
o
sa
p
e
n
ta
e
n
o
ic
a
c
id
[E
P
A
(d
5
)]
F
a
tt
y
a
c
yl
s
B
io
sy
n
th
e
si
s
o
f
u
n
sa
tu
ra
te
d
fa
tt
y
a
c
id
s
3
3
0
.2
4
5
6
1
5
.5
5
−
7
.5
9
−
8
.1
3
−
1
5
.9
4
C
1
6
5
3
1
D
o
c
o
se
n
o
yl
-C
o
A
F
a
tt
y
a
c
yl
s
B
io
sy
n
th
e
si
s
o
f
u
n
sa
tu
ra
te
d
fa
tt
y
a
c
id
s
1
0
8
8
.4
3
5
4
1
4
.6
9
−
3
.9
4
−
1
1
.0
5
−
1
0
.9
4
C
0
2
9
3
9
/
H
M
D
B
0
1
1
1
3
Is
o
va
le
ry
l-
C
o
A
F
a
tt
y
a
c
yl
s
V
a
lin
e
,
le
u
c
in
e
a
n
d
is
o
le
u
c
in
e
d
e
g
ra
d
a
tio
n
8
7
4
.1
6
2
2
0
.6
3
−
1
0
.5
5
+
5
.2
2
−
1
4
.1
4
(C
o
n
ti
n
u
e
d
)
Frontiers in Microbiology | www.frontiersin.org 14 March 2017 | Volume 8 | Article 536
Yap et al. Metabolic Dynamics following H. pylori Eradication
T
A
B
L
E
2
|
C
o
n
ti
n
u
e
d
K
E
G
G
/
H
M
D
B
/
L
M
ID
M
e
ta
b
o
li
te
C
la
s
s
P
a
th
w
a
y
m
/z
R
T
(m
in
)
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
6
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
1
2
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
1
8
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
1
4
8
2
7
/
L
M
FA
0
2
0
0
0
0
1
2
9
(S
)-
H
p
O
D
E
F
a
tt
y
a
c
yl
s
L
in
o
le
ic
a
c
id
m
e
ta
b
o
lis
m
3
1
1
.2
2
2
9
1
6
.6
6
+
4
.1
2
+
1
0
.2
6
−
8
.3
2
C
0
4
7
1
7
/
L
M
FA
0
2
0
0
0
0
3
4
1
3
(S
)-
H
p
O
D
E
F
a
tt
y
a
c
yl
s
L
in
o
le
ic
a
c
id
m
e
ta
b
o
lis
m
3
3
5
.2
2
0
6
1
3
.7
3
+
1
.5
2
−
3
.2
4
+
2
.9
6
C
1
6
3
1
8
/
L
M
FA
0
2
0
2
0
0
1
6
m
e
th
yl
(+
)-
7
-i
so
ja
sm
o
n
a
te
F
a
tt
y
a
c
yl
s
a
lp
h
a
-L
in
o
le
ic
a
c
id
m
e
ta
b
o
lis
m
2
2
3
.1
3
3
7
1
5
.5
8
+
1
.8
9
+
5
.7
8
-8
.2
7
C
0
5
9
8
4
/
H
M
D
B
0
0
0
0
8
D
L
-a
-H
yd
ro
xy
b
u
ty
ric
a
c
id
F
a
tt
y
a
c
yl
s
P
ro
p
a
n
o
a
te
m
e
ta
b
o
lis
m
1
0
3
.0
4
0
3
0
.6
1
+
0
.5
7
−
0
.2
6
−
1
9
.0
2
C
0
1
1
2
0
/
H
M
D
B
0
1
3
8
3
/
L
M
S
P
0
1
0
5
0
0
0
2
S
p
h
in
g
a
n
in
e
1
-p
h
o
sp
h
a
te
S
p
h
in
g
o
lip
id
s
S
p
h
in
g
o
lip
id
m
e
ta
b
o
lis
m
3
8
2
.2
7
1
6
1
6
.1
6
−
1
0
.3
8
−
1
7
.5
0
−
1
7
.5
0
C
0
6
1
2
4
/
L
M
S
P
0
1
0
5
0
0
0
1
S
p
h
in
g
o
si
n
e
-1
-p
h
o
sp
h
a
te
S
p
h
in
g
o
lip
id
s
S
p
h
in
g
o
lip
id
m
e
ta
b
o
lis
m
3
7
8
.2
4
0
5
1
5
.5
1
−
1
4
.1
2
−
1
4
.1
3
−
2
.7
2
C
1
2
1
4
4
/
H
M
D
B
0
4
6
1
0
/
L
M
S
P
0
1
0
3
0
0
0
1
P
h
yt
o
sp
h
in
g
o
si
n
e
S
p
h
in
g
o
lip
id
s
S
p
h
in
g
o
lip
id
m
e
ta
b
o
lis
m
3
1
8
.3
0
0
4
1
3
.9
4
−
5
.9
1
−
1
2
.9
3
−
1
7
.4
8
C
0
3
0
3
3
/
H
M
D
B
1
0
3
2
0
C
o
rt
o
lo
n
e
-3
-g
lu
c
u
ro
n
id
e
S
te
ro
ll
ip
id
s
E
st
ro
g
e
n
m
e
ta
b
o
lis
m
5
4
3
.2
8
0
2
1
0
.6
3
+
3
.4
9
+
2
.3
3
−
1
0
.5
4
C
0
5
4
6
4
/
H
M
D
B
0
0
6
3
1
G
ly
c
o
d
e
o
xy
c
h
o
la
te
S
te
ro
ll
ip
id
s
S
e
c
o
n
d
a
ry
b
ile
a
c
id
b
io
sy
n
th
e
si
s
4
5
0
.3
2
0
7
1
4
.8
6
+
4
.8
1
−
4
.4
5
−
2
.5
2
C
0
5
1
2
2
/
H
M
D
B
0
0
0
3
6
/
L
M
S
T
0
5
0
4
0
0
0
1
Ta
u
ro
c
h
o
lic
a
c
id
S
te
ro
ll
ip
id
s
P
rim
a
ry
a
n
d
S
e
c
o
n
d
a
ry
b
ile
a
c
id
5
3
3
.3
2
5
6
1
2
.0
3
+
7
.7
3
+
8
.2
7
−
1
.3
5
b
io
sy
n
th
e
si
s
C
0
5
4
6
5
/
H
M
D
B
0
0
9
5
1
/
L
M
S
T
0
5
0
4
0
0
0
5
Ta
u
ro
c
h
e
n
o
d
e
o
xy
c
h
o
lic
a
c
id
S
te
ro
ll
ip
id
s
P
rim
a
ry
a
n
d
S
e
c
o
n
d
a
ry
b
ile
a
c
id
b
io
sy
n
th
e
si
s
5
0
0
.3
0
4
0
1
3
.6
0
+
2
.6
4
+
2
.9
2
−
3
.8
2
C
0
3
0
3
3
/
H
M
D
B
0
2
5
7
9
/
L
M
S
T
0
5
0
1
0
0
4
8
G
ly
c
o
c
h
e
n
o
d
e
o
xy
c
h
o
lic
a
c
id
3
-g
lu
c
u
ro
n
id
e
S
te
ro
ll
ip
id
s
P
e
n
to
se
a
n
d
g
lu
c
o
ro
n
a
te
in
te
rc
o
n
ve
rs
io
n
s
S
ta
rc
h
a
n
d
su
c
ro
se
m
e
ta
b
o
lis
m
B
ile
se
c
re
tio
n
6
2
6
.3
5
3
9
1
2
.9
7
−
5
.6
8
−
1
7
.0
1
−
1
7
.0
1
C
0
3
0
3
3
/
H
M
D
B
1
0
3
5
1
1
1
-b
e
ta
-
h
yd
ro
xy
a
n
d
ro
st
e
ro
n
e
-3
-
g
lu
c
u
ro
n
id
e
S
te
ro
ll
ip
id
s
P
e
n
to
se
a
n
d
g
lu
c
o
ro
n
a
te
in
te
rc
o
n
ve
rs
io
n
s
S
ta
rc
h
a
n
d
su
c
ro
se
m
e
ta
b
o
lis
m
B
ile
se
c
re
tio
n
4
8
1
.2
4
3
1
9
.2
2
+
4
.1
8
+
3
.5
0
−
1
1
.5
9
(C
o
n
ti
n
u
e
d
)
Frontiers in Microbiology | www.frontiersin.org 15 March 2017 | Volume 8 | Article 536
Yap et al. Metabolic Dynamics following H. pylori Eradication
T
A
B
L
E
2
|
C
o
n
ti
n
u
e
d
K
E
G
G
/
H
M
D
B
/
L
M
ID
M
e
ta
b
o
li
te
C
la
s
s
P
a
th
w
a
y
m
/z
R
T
(m
in
)
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
6
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
1
2
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
o
m
p
a
ri
s
o
n
o
f
E
x
p
re
s
s
io
n
le
v
e
l
a
t
1
8
m
o
n
th
s
p
o
s
t-
e
ra
d
ic
a
ti
o
n
to
B
a
s
e
li
n
e
a
C
0
3
0
3
3
/
H
M
D
B
1
0
3
5
7
Te
tr
a
h
yd
ro
a
ld
o
st
e
ro
n
e
-3
-
g
lu
c
u
ro
n
id
e
S
te
ro
ll
ip
id
s
P
e
n
to
se
a
n
d
g
lu
c
o
ro
n
a
te
in
te
rc
o
n
ve
rs
io
n
s
5
5
8
.2
9
0
7
1
3
.3
7
+
6
.0
4
−
7
.4
0
−
1
1
.8
8
S
ta
rc
h
a
n
d
su
c
ro
se
m
e
ta
b
o
lis
m
B
ile
se
c
re
tio
n
C
0
3
6
4
2
/
H
M
D
B
0
2
5
8
0
/
L
M
S
T
0
5
0
2
0
0
0
3
Ta
u
ro
lit
h
o
c
h
o
lic
a
c
id
3
-s
u
lfa
te
S
te
ro
ll
ip
id
s
B
ile
se
c
re
tio
n
5
6
2
.2
4
9
2
1
1
.6
6
+
0
.5
3
−
1
4
.5
6
−
1
4
.5
6
C
0
5
3
0
0
/
H
M
D
B
0
0
3
3
5
/
L
M
S
T
0
2
0
1
0
0
4
1
1
6
a
lp
h
a
-H
yd
ro
xy
e
st
ro
n
e
S
te
ro
ll
ip
id
s
S
te
ro
id
h
o
rm
o
n
e
b
io
sy
n
th
e
si
s
2
8
7
.1
6
5
5
1
2
.5
7
−
6
.0
1
−
6
.0
1
−
6
.0
1
C
1
1
1
3
6
/
L
M
S
T
0
5
0
1
0
0
1
4
E
tio
c
h
o
la
n
-3
α
-o
l-
1
7
-o
n
e
3
-g
lu
c
u
ro
n
id
e
S
te
ro
ll
ip
id
s
S
te
ro
id
h
o
rm
o
n
e
b
io
sy
n
th
e
si
s
4
6
5
.2
4
7
7
1
1
.0
9
+
2
.2
0
−
3
.6
1
−
1
4
.8
C
1
8
0
4
3
/
H
M
D
B
0
0
6
5
3
/
L
M
S
T
0
5
0
2
0
0
1
6
C
h
o
le
st
e
ro
ls
u
lfa
te
S
te
ro
ll
ip
id
s
S
te
ro
id
h
o
rm
o
n
e
b
io
sy
n
th
e
si
s
4
6
5
.3
0
3
7
2
1
.4
7
−
8
.7
1
+
1
.6
5
−
4
.4
3
C
1
8
0
4
4
/
H
M
D
B
0
0
7
7
4
/
L
M
S
T
0
5
0
2
0
0
1
4
P
re
g
n
e
n
o
lo
n
e
su
lfa
te
S
te
ro
ll
ip
id
s
S
te
ro
id
h
o
rm
o
n
e
b
io
sy
n
th
e
si
s
3
9
5
.1
8
9
1
1
3
.2
0
−
1
.3
2
+
1
2
.4
3
−
1
.3
2
C
0
5
4
7
3
/
L
M
S
T
0
2
0
3
0
1
8
7
1
1
b
,2
1
-D
ih
yd
ro
xy
-3
,2
0
-o
xo
-
5
b
-p
re
g
n
a
n
-1
8
-a
l
S
te
ro
ll
ip
id
s
S
te
ro
id
h
o
rm
o
n
e
b
io
sy
n
th
e
si
s
3
6
3
.2
1
7
1
1
1
.0
8
−
5
.7
8
−
9
.2
7
−
8
.8
9
C
0
5
4
7
1
/
H
M
D
B
0
3
2
5
9
/
L
M
S
T
0
2
0
3
0
2
0
4
D
ih
yd
ro
c
o
rt
is
o
l
S
te
ro
ll
ip
id
s
S
te
ro
id
h
o
rm
o
n
e
b
io
sy
n
th
e
si
s
3
6
5
.2
3
1
8
1
0
.6
8
+
0
.8
3
+
2
.4
6
−
6
.4
4
C
0
5
6
8
3
/
2
-
A
m
in
o
e
th
yl
p
h
o
sp
h
o
c
h
o
la
te
S
te
ro
ll
ip
id
s
P
h
o
sp
h
o
n
a
te
a
n
d
p
h
o
sp
h
in
a
te
m
e
ta
b
o
lis
m
5
1
6
.3
0
6
5
1
7
.2
6
+
4
.7
0
+
1
6
.6
8
−
C
0
3
4
2
8
/
H
M
D
B
0
1
2
7
8
/
L
M
P
R
0
1
0
6
0
1
0
0
0
3
P
re
sq
u
a
le
n
e
d
ip
h
o
sp
h
a
te
P
re
n
o
ll
ip
id
s
C
h
o
le
st
e
ro
l
b
io
sy
n
th
e
si
s
6
0
4
.3
5
3
1
8
.3
4
+
7
.9
7
+
8
.5
4
+
3
.6
6
a
E
xp
re
s
s
io
n
le
ve
li
n
d
ic
a
te
s
lo
g
2
fo
ld
c
h
a
n
g
e
(F
C
).
+
in
d
ic
a
te
s
u
p
-r
e
g
u
la
te
d
in
p
o
s
t-
e
ra
d
ic
a
ti
o
n
g
ro
u
p
;
−
in
d
ic
a
te
s
d
o
w
n
-r
e
g
u
la
te
d
in
p
o
s
t-
e
ra
d
ic
a
ti
o
n
g
ro
u
p
.
Frontiers in Microbiology | www.frontiersin.org 16 March 2017 | Volume 8 | Article 536
Yap et al. Metabolic Dynamics following H. pylori Eradication
(Pulimeno et al., 2013; Amaral et al., 2014a; Cipolla-Neto et al.,
2014; Sharma et al., 2015). Taken together, the down-regulation
of 5-Hydroxytryptophan and melatonin in plasma post-H. pylori
eradication may be associated with the protective effect of
H. pylori against metabolic disorders.
6-phosphogluconic acid, in the pentose phosphate pathway,
was elevated at 6 months post-eradication. This finding is
in agreement with that of a previous study on hepatic gene
expression whereby it was reported that the pentose phosphate
pathway was up-regulated in obese patients with type 2 diabetes
(Takamura et al., 2008). An in vivo study also demonstrated
significance increase of G6PD expression and activity, NADPH
levels, and 6-phosphogluconic acid generation in the liver of
adult male Zucker fa/fa rats, a prototype model of hyperglycemia
and type 2 diabetes (Gupte et al., 2009). Therefore, the elevation
of 6-phosphogluconic acid at 6 months post-eradication could be
a metabolic signature of metabolic disorders. However, it seems
likely the expression of this metabolite was restored to Baseline
level at 12 and 18 months post-eradication.
N-Methyl-4-pyridone-3-carboxamide is one of the end
products of nicotinamide-adenine dinucleotide (NAD)
degradation. This metabolite was initially up-regulated at 6
months post-eradication but it was down-regulated at 12 and 18
months post-eradication. NAD is one of the cofactors essential
for redox reactions. NAD and NADP play pivotal roles in
metabolic conversions as signal transducers and in cellular
defense systems in which they participate as electron carriers in
energy transduction and biosynthetic processes (Pollak et al.,
2007). This observation indicated that H. pylori eradication may
affect the biosynthesis of NAD in nicotinate and nicotinamide
metabolism and hence, it corroborated with our previous finding
that H. pylori eradication may affect the regulation of energy
metabolism in the human body (Yap et al., 2015).
Citric acid and flavin adenine dinucleotide (FAD), an
intermediate and a cofactor of the tricarboxylic acid cycle (TCA),
were changed post-H. pylori eradication. In human beings, the
TCA cycle together with oxidative phosphorylation, provides
more than 95% of energy used by aerobic cells (Berg et al., 2002).
In addition, accumulating evidence has emphasized the vital roles
of gut microbiota in energy harvest and metabolism in hosts
(Bäckhed et al., 2004; Musso et al., 2010; Velagapudi et al., 2010;
Venema, 2010), which are thought to be associated with various
diseases such as obesity and diabetes. The down-regulation of
these metabolites at 12 and 18 months post-eradication could
probably reflect the long term effect of H. pylori eradication
on regulation of energy metabolism in which the eradication of
this bacterium causes the perturbations of the gut microflora
and therefore, it affects regulation of energy metabolism and
subsequently leads to development of metabolic disorders such
as obesity. This result could be an example to demonstrate the
role of gut bacteria on plasma metabolite profile.
N1,N12-diacetylspermine is an acetylated product of
spermidine and spermine controlled by spermidine-
spermineN1-acetyltransferase (SSAT) using acetyl-CoA as
substrate. Polyamines (putrescine, spermine and spermidine)
are organic polycations that are important for various cellular
functions such as cell growth, cancer and aging of which its
metabolism is tightly controlled (Pegg and Casero, 2011). Both
in vivo and in vitro studies have shown that polyamine pathway
plays a major role in energy homeostasis (Jell et al., 2007; Kraus
et al., 2014). The up-regulation of N1,N12-diacetylspermine at 6
and 12 months post-eradication but with no significant changes
at 18 months-post eradication may indicate the dysregulation
of polyamine metabolism which could be a potential predictive
signature of metabolic disorders such as obesity.
Studies also showed that the increase in blood concentrations
of selected essential amino acids and their derivatives, in
particular, branched-chain amino acids (BCAA), aromatic amino
acids (Adams, 2011), and the decreases in the metabolism
of essential fatty acids (linoleic and α-linoleic acids) and
polyunsaturated fatty acids [such as eicosapentaenoic acid
(EPA)] (Das, 2006), are believed to play an important role
in the pathophysiology of several diseases including obesity.
Correspondingly, in this study, we found that a cofactor
involved in the metabolism of BCAA, isovaleryl-CoA, as well
as numerous small molecules involved in aromatic amino
acid metabolisms (tryptophan, tyrosine and phenylalanine
metabolisms) were perturbed followingH. pylori eradication and
these small molecules were all down-regulated at 18 months-
post eradication. The decrease in the metabolisms of BCAA
and aromatic amino acids following H. pylori eradication could
indirectly lead to the accumulation of these amino acids in
the blood. The intermediates involved in the essential fatty
acid metabolisms (linoleic and α-linoleic acids metabolism) and
the polyunsaturated fatty acid EPA were down-regulated at
18 months post-H. pylori eradication as well. Therefore, these
dysregulated fatty acid and amino acid metabolisms may be
associated with the future onset of metabolic disorders.
Following H. pylori eradication was the down-regulation
of tetrapyrroles and derivatives that are involved in heme
biosynthesis and bilirubin degradation. Coproporphyrinogen III,
protoporphyrin IX, hematoporphyrin, and harderoporphyrin
are naturally occurring porphyrins, intermediates that play an
important role in heme biosynthesis. Heme is critical also for
the biological functions of several enzymes, such as cytochromes
(Ajioka et al., 2006). The down-regulation of porphyrins is
another observation that may support our previous findings
that H. pylori eradication may affect the regulation of energy
metabolism and hence, possibly lead to the development of
metabolic disorders such as obesity (Yap et al., 2015).
The synthesis of bile acids (BAs) is the key pathway
of cholesterol catabolism in human. BAs are now regarded
as metabolic integrators of whole-body energy homeostasis
(Du et al., 2013). BAs can influence glucose and lipid
metabolism through the activation of farnesoid X receptor
(FXR), lowers plasma triglyceride (TG) synthesis and/or
the modulation of glucose-induced lipogenic genes (Lefebvre
et al., 2009). Furthermore, previous studies have shown that
the importance of intestinal bacteria on the metabolism of
BAs (Cummings and Macfarlane, 1997) and modulation of
lipid metabolism (Velagapudi et al., 2010). Up-regulation of
prequalene diphosphate, an intermediate involved in cholesterol
biosynthesis, was probably linked to the increase of bile acid in
the post-H. pylori eradication plasma.We also identified two BAs,
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taurocholic acid and taurochenodeoxycholic acid in which they
were up-regulated at 6 and 12 months post-H. pylori eradication
but down-regulated at 18 months-post eradication. Consistently,
majority of the TG in our study were found to be down-regulated
at 6 and 12 months post-H. pylori eradication (File S1). Hence,
the elevation of BAs in the plasma could also be the indication
of possibility of future onset of metabolic disorders. However, at
18 months post-eradication, the bile acids in plasma were down-
regulated instead, and strange enough, majority of the plasma TG
were still down-regulated as compared to Baseline.
Altered Oxidative Stress and Its
Association with Immunological Disorders
The down-regulation of Biliverdin IX, which acts as the
precursor of biosynthesis of bilirubin, as well as uribilinoids
(Mesobilirubinogen and L-Urobilinogen) and urobilins (I-
Urobilin and L-Urobilin), which are by-products of bilirubin
degradation could be associated with the down-regulation of
cellular antioxidant activity. Bilirubin is a lipophilic linear
tetrapyrrole found abundantly in blood plasma of mammals. It
is the final product of heme catabolism. The first major step
of heme catabolic pathway involves the formation of water-
soluble biliverdin from heme by heme oxygenase (HO) which is
subsequently reduced by biliverdin reductase (BVR) to bilirubin
(Baranano et al., 2002). Studies have shown that bilirubin is
a main physiologic antioxidant cytoprotectant (Stocker et al.,
1987; Baranano et al., 2002; Kapitulnik, 2004; Sedlak et al.,
2009) which can protect cells from a 10,000-fold excess of H2O2
(Baranano et al., 2002; Sedlak et al., 2009). The down-regulation
of biliverdin IX in plasma post-H. pylori eradication may indicate
low concentration of bilirubin in tissues that leads to marked
increase of reactive oxygen species in the tissue levels and causes
apoptotic cell death (Baranano et al., 2002; Sedlak et al., 2009).
In addition, it has been reported that oxidative stress may play
a crucial role in the pathogenesis of asthma. For instance, Ohrui
et al. reported a case of significant relief of asthma symptoms
during jaundice (Ohrui et al., 2003). On the other hand,
accumulating evidence suggests that bilirubin also possesses
immunomodulatory properties (Nejedlá, 1970; Veˇtvicˇka et al.,
1985; Haga et al., 1996; Kirkby and Adin, 2006; Liu et al., 2008)
and may protect mammals against autoimmune diseases (Liu
et al., 2008). Therefore, the down-regulation of Biliverdin IX and
by-products of bilirubin following H. pylori eradication could
be related to the negative association of H. pylori with asthma
and allergy (Amedei et al., 2006, 2010; Blaser et al., 2008) and
autoimmune diseases (Sawalha et al., 2004; Ram et al., 2013)
where H. pylori may have protective effect against some of the
immunological disorders.
Altered Sphingolipid Metabolism and Its
Association with Inflammation
Ceramide, sphingosine, sphingosine 1-phosphate (S1P),
and ceramide-1-phosphate (C1P) are the main bioactive
sphingolipids that act as signaling molecules to regulate
physiological events such as cell proliferation, apoptosis, and
inflammation (Futerman and Hannun, 2004; Hannun and
Obeid, 2008; Morad and Cabot, 2013). Ceramide is an important
molecule in sphingolipid metabolism (KEGG: map00600)
and a precursor of complex sphingolipids. S1P has strong
proinflammatory properties. It activates neutrophils and
macrophages and further induces mast cells degranulation.
S1P also stimulates cyclooxygenase 2 (COX2), thus leading to
production of inflammatory mediators (Takeuchi et al., 2006).
It is known that colonization of the stomach by H. pylori can
result in chronic gastritis, and in minority cases, it causes
the development of peptic ulcers at the site of colonization
(Kusters et al., 2006). Eradicating H. pylori can permanently
cure of most gastric and duodenal ulcers. In our study, following
H. pylori eradication, the down-regulation of S1P, sphinganine
1-phosphate and phytosphingosine could probably be related to
the reduction of sub-clinical inflammation in the stomach lining.
These observations probably complimented with the down-
regulation of fecal pytosphingosine post- H. pylori eradication.
It is important to note that we also observed significant changes
of ceramides and other more complex sphingolipids, such as
glucosylceramides, and lactosylceramide in the plasma but they
did not display a consistent pattern of expression (File S2).
Studies have shown that lipid metabolism in blood could be
impacted by the changes of gut microbiota (Velagapudi et al.,
2010). Thus, changes of expression of sphingolipids in this study
may reflect another aspect of the influence of gut microflora on
biochemical reactions in blood.
Others
On filtering out exogenous plasma metabolites
that were not produced by the human body, two
hopanoids produced by Proteobacteria in the plasma,
bacteriohopane-,32,33,34-triol-35-cyclitolguanine and 2-
methyl-32,35-anhydrobacteriohopanetetrol, were detected that
may be correlated with the Proteobacteria hopanoid (32,35-
anhydrobacteriohopaneterol) found in fecal lipidome. Similar
to the hopanoid found in fecal lipidome, these two plasma
hopanoids were also down-regulated post-H. pylori eradication
(File S3). This observation was yet again another instance that
indicates changes in the gut microbiota (local) impact the
systemic changes of human body following H. pylori eradication.
Beside the loss of H. pylori, proton pump inhibitors and
antibiotics may also influence the human gut microbiome,
fecal lipidome, and plasma metabolome. Several studies had
demonstrated that proton pump inhibitor causes significant
shifts in microbiome composition, diversity and function (Bajaj
et al., 2014; Imhann et al., 2016; Jackson et al., 2016). However,
the long-term effects proton pump inhibitors are unknown. The
effects of antibiotic therapy on the gut microbiome defers among
individuals and antibiotics used (Jakobsson et al., 2010; Zaura
et al., 2015). Zaura et al. (2015) showed that clindamycin and
ciprofloxacin can cause severe and long-term impact on the
health-associated butyrate-producing microbial community of
the gut while amoxicillin treatment only resulted in dissimilarity
between baseline and week-1 samples compared to placebo group
in feces. The diversity of the microbiota has been reported to
recover to resemble the pre-treatment states by the end of 1 year
after clarithromycin, metronidazole and omeprazole treatment,
the microbiota remained perturbed in some cases for up to 4
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FIGURE 6 | The local and systemic effects of H. pylori eradication.
years post treatment (Jakobsson et al., 2010). The present study
could not definitely attribute these observations to the loss of
H. pylori as we were unable to rule out completely the influences
of triple therapy used for H. pylori eradication.
CONCLUSIONS
The local and systemic effects of H. pylori eradication and the
proposed mechanisms underlying the association of H. pylori
eradication with human metabolic and immunological disorders
are summarized in Figure 6. In conclusion, non-targeted fecal
lipidomics and plasma metabolomics revealed that H. pylori
eradication dramatically changed many global metabolite/lipid
features, with the majority of metabolites being down-regulated.
We have proposed the influence of gut microbiota on the
systemic changes of human body. Our findings primarily
implicate the perturbation of gut microbiota following H. pylori
eradication may affect the energy and lipid metabolism in human
which could eventually lead to the development of metabolic
disorders. The predictive metabolic signature of metabolic and
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immunological disorders following H. pylori eradication gave
us insights on the intricate and complex interaction of H. pylori
and gut microbiota in modulating human health and therefore,
a point to ponder upon in future management of H. pylori
infection.
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